Trial Profile
Phase I Clinical Trial of Venetoclax (ABT-199) in Combination With Ixazomib and Dexamethasone for Patients With Relapsed Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2024 Status changed from active, no longer recruiting to completed.
- 21 Jul 2023 Planned End Date changed from 2 Dec 2023 to 1 Mar 2024.
- 24 Apr 2023 Planned End Date changed from 2 Mar 2023 to 2 Dec 2023.